Trends in Manufacturing and Equipment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Trends in Manufacturing and Equipment
Pharmaceutical Technology's survey of finished drug-product manufacturing equipment and trends shows gains in process analytical technology and indicates innovation areas.


Pharmaceutical Technology
Volume 38, Issue 7, pp. 28-31
Dan Ward; Nicholas Eveleigh/Maria Toutoudaki/Getty Images

Pharmaceutical Technology’s annual equipment and manufacturing survey collected industry feedback on trends and the utility of equipment used in finished drug-product manufacturing. Respondents to both solid-dosage and parenteral drug manufacturing questions indicated overall satisfaction with existing equipment and equipment innovation. Data indicated that process analytical technology (PAT) is growing in use, but some users also noted a need for improvement in existing PAT equipment and in new solutions. A majority of respondents continue to view quality-by-design (QbD) principles as important, and more than 90% of respondents have a positive view of metrics and trend analysis. Responses also indicated further growth in continuous manufacturing and in manufacturing of highly potent drugs. Other areas of innovation to watch include robotics and software.

RELATED CONTENT

Evaluating Equipment Utility and Innovation

Optimizing Solid Dosage Manufacturing

More Manufacturing Topics

Solid-dosage equipment
Existing solid-dosage equipment is generally meeting industry needs. Only one area—PAT/in-process testing—was indicated as poor or inadequate by more than one-third of respondents (see Figure 1). Nearly one quarter of respondents also indicated that innovation is lacking in this area. This dissatisfaction is up from 2013, in which 22% indicated existing equipment was poor or inadequate and 16% said innovation was poor (1). It is interesting to note that use of PAT also increased over the past year among those surveyed. Process control/automation and powder transfer/materials handling were also flagged as needing significant improvement in existing equipment (25% and 21% respectively) and in innovation (17% and 12%); these areas were also noted in 2013.

Continuous manufacturing
The percentage of respondents involved in solid-dosage manufacturing that use continuous processes either overall or in select unit operations was nearly 40%, which was similar to 2013. Respondents expressed greater confidence in the evolution of continuous solid-dosage manufacturing, with nearly 85% predicting that the technology would evolve to allow fully continuous processing; in 2013, only 67% predicted such development of the technology. Just over one-third of respondents, however, predicted that the industry would only apply continuous processing to select operations even if fully continuous processes are available. Several individuals commented that, although continuous processing would work for high volumes, they didn’t see it being appropriate for small batch sizes. Half the respondents noted cost as a barrier to implementing continuous manufacturing, and over 40% also identified lack of expertise and insufficient PAT as barriers.

Parenteral equipment
The majority of parenteral-equipment respondents indicated that existing equipment is good or excellent, as shown in Figure 2. These respondents also agreed that innovation is generally keeping pace with most, if not all, of their needs. Innovation was rated as excellent or good in lyophilization (95%), barrier isolation (91%), disposables (91%), vial and cartridge fill-finish equipment (92%), and prefilled-syringe fill-finish equipment (85%). Process control and automation was a weaker area, similar to 2013, with approximately 25% saying that existing equipment is either poor or inadequate, and 18% saying that innovation is poor.

High-potency and high-containment
Just over one-third of respondents (in either solid-dosage or parenteral manufacturing) are involved with high-containment or high-potency manufacturing either in-house or at outsourced facilities. This percentage was up just slightly from last year’s survey; however, in 2014, 78% indicated an increase in their company’s level of activity over the past year up from 53% in 2013. When asked to identify the most challenging equipment or processing area, respondents’ answers were diverse, with 21% each indicating system setup/changeover and getting materials into or out of the system during production. Other areas chosen as the biggest challenge included containment (17%), ergonomics (14%), air flow (10%), environmental issues (9%), and personnel protection (7%).  Training and cleaning validation were also identified as challenges.

Figure 1: Utility of existing solid-dosage equipment.

Equipment metrics
Those surveyed overwhelmingly agreed that metrics and trend analysis enhance the ability to improve equipment operation (92% of respondents). Actual use of metrics lagged this response somewhat. Approximately 75% stated that they use trend analysis to measure process or product deviations and relate this to equipment performance; 73% report that their company culture encourages optimizing manufacturing quality using metrics and trend analysis. Approximately 66% of respondents said their company has a metric(s) specifically to measure unplanned downtime of equipment (i.e., equipment failure).  

Figure 2: Utility of existing parenteral equipment.

In both solid-dosage and parenteral areas, approximately half of respondents were aware of an equipment failure that had led to significant downtime or quality problems in the past year. When asked to identify the root cause(s), contamination or cleaning problems were most frequently chosen (44%), followed by utilities (37%), process validation (26%), nonconformance (25%), and other (11%) (multiple selections were allowed).

QbD
The majority of respondents use QbD principles in their manufacturing processes to some extent (see Figure 3). Approximately 35% apply QbD to all processes for new or all products, and nearly 43% apply QbD to select processes. Almost 22% indicated that they do not use QbD principles. Respondents noted several different challenges to implementing or barriers to using QbD (multiple answers allowed). The challenge most frequently identified was lack of knowledge or training (nearly 60% of respondents). Other challenges included  lack of clarity in regulatory guidance (40%), management buy-in (38%), and availability of necessary equipment (35%) and software tools (31%). Nearly 10% said they saw no barriers or challenges.

Figure 3: Application of quality-by-design (QbD) principles (% of respondents).

PAT
In the five manufacturing areas surveyed, the use of PAT increased significantly since 2013 (see Figure 4), with 32-46% of respondents in 2014 indicating that they currently use PAT compared to 13-21% of respondents in 2013 (1). The primary drivers for using PAT (multiple answers possible) include better process understanding (56%), increased efficiency (39%), reduced costs (34%), and shorter process times (30%). The use of PAT should continue to grow; between 20 and 30% of respondents in 2014 indicate plans to implement PAT in the coming year. Approximately one-third of respondents (33-37% depending on the application), however, do not currently use PAT and do not plan to implement it in the coming year.

Figure 4: Use of process analytical technology.

Areas for innovation
Given these plans to implement PAT and the respondents who said that existing PAT tools do not meet their needs, as discussed previously, PAT is an area ripe for suppliers to develop new and improved instruments.

When asked about the most important area for innovation in pharmaceutical manufacturing, respondents mentioned some of the topics surveyed, such as continuous processing, QbD, and PAT, and several respondents listed automation. “Robotics are an inevitability,” said one, and another commented, “Running ‘lights out’ [i.e., fully automated] would reduce the amount of hands-on time for production personnel.” Related comments included calls for improved software to eliminate human error. A wide range of methods and technologies, including those evaluated in this survey, will play a role in the continued drive to improve product quality and process efficiency.

Respondent’s profiles

Pharmaceutical Technology’s Equipment and Manufacturing Survey targeted individuals in production and engineering. The survey was conducted by email from February to May 2014 and had 254 respondents. Approximately 36% were from innovator pharmaceutical companies, 29% were from generic-drug companies, 18% were from contract manufacturers, and 9% were from consumer healthcare companies making over-the-counter products. The remaining respondents (less than 5% each) included excipient and raw material suppliers, equipment or machinery vendors, consultants, and members of universities. Approximately 60% of the respondents were involved with solid-dosage manufacturing and the other 40% in parenteral drug manufacturing. The majority of respondents (69%) were from companies with under $1 billion in revenue. More than 13% were from companies with between $1-10 billion in revenue, approximately 10% were from companies with $10-50 billion in revenue, and the remainder (8%) were from companies with over $50 billion in revenue.

Reference
1. J. Markarian, Pharm. Technol. 37 (4)  110-113 (2013).

About the Author
Jennifer Markarian is the manufacturing editor for Pharmaceutical Technology.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here